Dual Targeting of the HER2 Receptor
Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.
Clinical Pearls
Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.
- Dual targeting of the HER2 receptor proved to better than single targeting, resulting in an improvement in pathological complete remission
- Presence of a pathological complete remission correlated with increased disease-free survival and overall survival in patients with hormone receptor-positive and hormone receptor-negative disease
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Real-World Data and AI Help Improve ILD Management in HER2+ Breast Cancer
December 13th 2024Project EVOLVE findings show how AI-driven real-world data analysis, combined with targeted educational interventions, can enhance adverse event monitoring and improve patient outcomes for those with HER2+ breast cancer.
Read More
